Bérubé Eugénie-Raphaëlle, Taillon Marie-Pierre, Furtado Milton, Garofolo Fabio
Algorithme Pharma Inc., Laval (Montreal) Quebec, H7V 4B3, Canada.
Bioanalysis. 2011 Sep;3(18):2097-105. doi: 10.4155/bio.11.190.
Being regulated by agencies' guidances, the importance of a robust validated bioanalytical method is crucial as it may impact the validity of the pharmacokinetic data generated. During blood collection and processing, the presence of hemolyzed plasma samples may occur and as a result its impact must be investigated to ensure method robustness. Indeed, hemolyzed samples may affect the analyte recovery efficiency, as well as the chromatography. Furthermore, the stability of an analyte in hemolyzed plasma can be an issue as analyte degradation may occur. In this article we report two case studies where the analyte instability was a result of sample hemolysis. A description of the appropriate actions undertaken for the resolution of the issue will be discussed.
受各机构指南的规范,可靠的经过验证的生物分析方法至关重要,因为它可能会影响所生成的药代动力学数据的有效性。在血液采集和处理过程中,可能会出现溶血血浆样本,因此必须研究其影响以确保方法的稳健性。实际上,溶血样本可能会影响分析物的回收率以及色谱分析。此外,分析物在溶血血浆中的稳定性可能是一个问题,因为可能会发生分析物降解。在本文中,我们报告了两个案例研究,其中分析物不稳定是样本溶血的结果。将讨论为解决该问题而采取的适当措施的描述。